PCP
CDLX icon

Perbak Capital Partners’s Cardlytics CDLX Stock Holding History

Perbak Capital Partners’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,207
Closed -$2.35M – 58
2024
Q1 		$2.35M Buy
+16,207
New +$1.37M 2.95% 11

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PIP
PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BCM
Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perbak Capital Partners's CDLX Position: Q2 2024 in Review

Perbak Capital Partners sold out of Cardlytics (CDLX) in Q2 2024, closing a stake of 16,207 shares — an estimated $2.35M sold.

Perbak Capital Partners first reported a position in CDLX in Q1 2024 and held it in 1 quarter. The position peaked at $2.35M in Q1 2024. 127 funds tracked by Wall St. Rank hold CDLX as of Q2 2024.

  • Perbak Capital Partners reported no remaining Cardlytics position as of Q2 2024 after selling out during the quarter.
  • Perbak Capital Partners sold 16,207 Cardlytics shares in Q2 2024, an estimated $2.35M.
  • Perbak Capital Partners first reported a position in Cardlytics in Q1 2024 and held it in 1 quarter.
  • Perbak Capital Partners's Cardlytics position peaked at $2.35M in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Cardlytics as of Q2 2024.

Based on Perbak Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.